Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis

Published:2018-12-04 Issue:2 Volume:22 Page:151-157
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Purmonen Timo¹^ORCID,Törmälehto Soili²³^ORCID,Wahlman Hanna¹,Puolakka Kari⁴

Affiliation:

1. Novartis Finland Oy, Espoo, Finland;

2. Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland;

3. Market Access Consulting MediSoili Oy, Kuopio, Finland;

4. South Karelia Social and Health Care District (Eksote), Lappeenranta, Finland

Funder

Novartis Finland Oy

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1551227

Reference25 articles.

1. Axial spondyloarthritis

2. The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis

3. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review

4. Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years;Rheumatology and Therapy;2021-11-27

2. Functional hindrance, comorbid depression and early development of restrictive lung disease are linked to ankylosing spondylitis patients’ withdrawal from the workforce;Revista Medico-Chirurgicala;2021-06-30

3. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective;International Journal of Rheumatic Diseases;2019-06-18

4. IL-17 inhibition in axial spondyloarthritis: current and future perspectives;Expert Opinion on Biological Therapy;2019-04-19

5. Secukinumab: A Review in Ankylosing Spondylitis;Drugs;2019-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3